








Influence of obesity on pharmacokinetics of  
























I found that the dose-normalized steady-state trough concentration ratio 
of orally administered cyclosporine A and tacrolimus in blood is increased in 
obese patients with a body mass index over 25 compared with other patients. 
In order to investigate the mechanisms involved in this increase, we 
examined the influence of obesity on tacrolimus pharmacokinetics in lean 
and obese Zucker rats, focusing on changes in drug-metabolizing enzyme 
cytochrome P-450 3a2 (Cyp3a2) and drug transporter P-glycoprotein (P-gp). 
Zucker rats fed a normal diet were given tacrolimus intravenously at a dose 
of 1.0 mg/kg or orally at a dose of 3.2 mg/kg. The blood concentrations of 
tacrolimus in obese rats were significantly higher than those in lean rats 
after administration via both routes. Total clearance and steady-state 
volume of distribution of tacrolimus were significantly decreased, and the 
bioavailability was increased in obese rats, compared with lean rats. Protein 
expression of Cyp3a2 in the liver was significantly decreased in obese rats, 
compared with lean rats, while P-gp in the small intestine was also 
significantly decreased in obese rats. These results suggest that the high 
blood concentration of tacrolimus in obese patients is a consequence of 






















では、CYP3A4および P-glycoprotein の基質となり Therapeutic Drug Monitoring対象薬物
でもある cyclosporine A および tacrolimus に焦点を当て、肥満時における血中濃度変化





を評価した。体格の指標として body mass index（BMI）値を用いて、BMI 18.5以下を痩
せ型群、BMI 18.5-25を標準群、BMI 25 以上を過体重および肥満群の 3群に分類した。
Cyclosporine Aおよび tacrolimus トラフ血中濃度を投与量で補正した C/D比の 3群間に
おける変動と C/D比と BMI値との相関性について検討を行った。 
次に、遺伝的肥満モデルラットである Zucker（fa/fa）ラットとその対象群として Zucker




パク発現レベルを real-time PCR法および western blotting法を用いて評価した。 
【結果・考察】 
 Cyclosporine A を投与された患者においては、肥満患者群では非肥満患者群と比べて
C/D比の上昇は認められず、また BMI値と C/D比に相関性は認められなかった（Figure 
1）。また、tacrolimus を投与された患者においては、肥満患者群では非肥満患者群と比
べて C/D比の上昇が認められ、BMI値と C/D比に正の相関がみられた（Figure 1）。
そこで次に、肥満状態における tacrolimus体内動態変動要因を明らかにするため、肥








部の P-glycoprotein タンパク発現レベルは低下していた（Figure 2, 3）。これらの結果


























Figure 1. Comparison of C/D ratio of cyclosporine A (A) and tacrolimus (B) 
among patients having various BMIs.  
*Significantly differences from low BMI patients at p < 0.05. 
 
  
      Lean (+/+)   Obese (fa/fa) 
i.v. AUC0→∞ (ng h/mL) 888  ± 50    1381  ± 90
* 
 
CLtot (mL/min/kg) 19.1  ± 1.1  
 
12.3  ± 0.8* 
 
MRT (h) 5.49  ± 0.21  
 
5.77  ± 0.28  
 
Vdss (L/kg) 6.29  ± 0.44  
 
4.26  ± 0.33* 
  t1/2 (h)   4.35  ± 0.43    5.39  ± 0.24  





323.9  ± 82.7  
 
72.2  ± 7.8* 
 
Tmax (h) 1.4  ± 0.5  
 
0.5  ± 0.1  
 
Cmax (ng/mL) 64.5  ± 35.3  
 
141.3  ± 43.5  










Table 1. Pharmacokinetic parameters of tacrolimus after intravenous and oral 
administration to lean (+/+) and obese (fa/fa) Zucker rats. 
 
Data are means ± S.E. (n =5-6). 
*Significantly different from the lean (+/+) group at p < 0.05; Student’s unpaired 
t-test. 
 
Figure 3. Western blot analysis of protein expression of P-glycoprotein and Cyp3a2 in the 
liver of lean (+/+) (open column) and obese (fa/fa) (closed column) Zucker rats. 
Data are means ± S.E. (n =6). 


















Figure 4. Western blot analysis of protein expression of P-glycoprotein and Cyp3a2 in the 
upper, middle and lower sites of the small intestine of lean (+/+) (open column) and 
obese (fa/fa) (closed column) Zucker rats. 
Data are means ± S.E. (n =5). 
*Significantly different from the lean (+/+) group at p < 0.05; Student’s unpaired t-test. 
 

